"Fibrinolytic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.
| Descriptor ID |
D005343
|
| MeSH Number(s) |
D27.505.519.421.750 D27.505.954.411.320 D27.505.954.502.427
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Fibrinolytic Agents".
Below are MeSH descriptors whose meaning is more specific than "Fibrinolytic Agents".
This graph shows the total number of publications written about "Fibrinolytic Agents" by people in this website by year, and whether "Fibrinolytic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 1 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 2 | 1 | 3 |
| 2007 | 2 | 1 | 3 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 5 | 0 | 5 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 4 | 0 | 4 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 1 | 2 | 3 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fibrinolytic Agents" by people in Profiles.
-
Comparative safety of tenecteplase vs alteplase for acute ischemic stroke. J Stroke Cerebrovasc Dis. 2024 Jan; 33(1):107468.
-
Team is brain: leveraging EHR audit log data for new insights into acute care processes. J Am Med Inform Assoc. 2022 12 13; 30(1):8-15.
-
Response by Flint et al to Letter Regarding Article, "Risk of Distal Embolization From tPA (Tissue-Type Plasminogen Activator) Administration Prior to Endovascular Stroke Treatment". Stroke. 2021 01; 52(1):e39-e40.
-
Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis. Am Heart J. 2021 02; 232:105-115.
-
Risk of Distal Embolization From tPA (Tissue-Type Plasminogen Activator) Administration Prior to Endovascular Stroke Treatment. Stroke. 2020 09; 51(9):2697-2704.
-
Screening for Peripheral Artery Disease Using the Ankle-Brachial Index: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018 07 10; 320(2):184-196.
-
Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty. J Arthroplasty. 2017 11; 32(11):3524-3528.e1.
-
The budget impact and cost-effectiveness of defibrotide for treatment of veno-occlusive disease with multi-organ dysfunction in patients post-hematopoietic stem cell transplant. J Med Econ. 2017 May; 20(5):453-463.
-
Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016 Jun 21; 164(12):826-35.
-
Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016 Jun 21; 164(12):804-13.